Pfizer (PFE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Pfizer

NYSE•Healthcare•Drug Manufacturers - General

$27.64+0.18(0.01%)After hours

Market Cap

$156.49B

P/E

36.1x

P/S

2.5x

P/B

1.8x

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

How this company scores

AverageMetricSide Score: 48/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (6/25).

Profitability12/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality15/25

Strengths

Strong margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 36.1x5y range 7.9x – 76.7x

Currently above its 18-quarter median.

P/S · 2.5x5y range 2.2x – 4.0x

Currently near its 20-quarter median.

P/B · 1.8x5y range 1.5x – 4.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 6.9% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $156.49B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $63.70B
Q. Revenue: $15.03B
TTM EBITDA: $20.40B
TTM Op. Income: $13.82B
Q. Op. Income: $3.06B
TTM Net Income: $4.33B
Q. Net Income: $-248.00M
EPS: $-0.04
Shares Out.: $5.70B

$63.70B in TTM revenue declined 0.2% YoY, reaching $15.03B last quarter. TTM EBITDA of $20.40B and TTM operating income of $13.82B show growth is flowing through to the bottom line. TTM net income of $4.33B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 72.8%
EBITDA Margin: 31.2%
Op. Margin: 20.4%
Net Margin: -1.6%

Op. margin of 20.4% is down 5.4% YoY — costs are rising relative to revenue. Net margin at -1.6% and gross margin of 72.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 21% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 36.1x
P/S Ratio: 2.5x
P/B Ratio: 1.8x

At 36.1x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.5x and P/B of 1.8x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $201.13B
Cash: $976.00M
Long-Term Debt: $60.49B
Book Value: $85.19B
D/E Ratio: 0.7
Debt/EBITDA: 12.9

With $201.13B in assets and $60.49B in long-term debt, D/E is 0.7and book value is $85.19B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 10% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $835.00M
TTM Free Cash Flow: $10.98B
FCF Margin: 17.2%
FCF / Net Income: 2.5

TTM FCF of $10.98B on $835.00M in operating cash flow. The FCF / Net Income ratio of 2.5x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.